Stryker Corporation 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
This filing covers the fiscal year ended December 31, 2024. Stryker Corporation is a global leader in medical technologies operating in two reportable segments: MedSurg and Neurotechnology and Orthopaedics. The company serves over 150 million patients annually across approximately 75 countries. In Q4 2024, Stryker reorganized its Spine business, reclassifying the Interventional Spine portfolio to Neuro Cranial and renaming the remaining business to Spinal Implants.
Key Financial Metrics
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Net Sales | $22,595 million | $20,498 million | +10.2% |
| Gross Profit | $14,440 million | $13,058 million | +10.6% |
| Gross Margin | 63.9% | 63.7% | +20 bps |
| Operating Income | $3,689 million | $3,888 million | -5.1% |
| Net Earnings (GAAP) | $2,993 million | $3,165 million | -5.4% |
| Diluted EPS (GAAP) | $7.76 | $8.25 | -5.9% |
| Adjusted Net Earnings | $4,700 million | $4,066 million | +15.6% |
| Adjusted Diluted EPS | $12.19 | $10.60 | +15.0% |
| Operating Cash Flow | $4,242 million | $3,711 million | +14.3% |
| Total Debt | $13,597 million | $12,995 million | +4.6% |
| Cash & Equivalents | $3,652 million | $2,971 million | +22.9% |
Material Changes vs. Prior Period
- Revenue Growth: Net sales grew 10.2% (10.7% in constant currency), driven by increased unit volume (+9.1%) and price increases (+1.1%). MedSurg and Neurotechnology grew 11.1%, while Orthopaedics grew 8.9%.
- Impairment Charges: GAAP operating income and net earnings were significantly impacted by $977 million in goodwill and other impairments. This included a $456 million goodwill impairment and a $362 million loss on assets held for sale related to the Spinal Implants business.
- Acquisitions: The company invested $1,628 million in acquisitions in 2024, including Vertos Medical and care.ai, expanding its portfolio in pain management and virtual care.
- Debt Refinancing: Stryker repaid $2,039 million in maturing debt and issued $3,011 million in new senior unsecured notes to extend its maturity profile.
Outlook, Risks, and Unusual Items
- Strategic Transactions: In January 2025, Stryker announced a definitive agreement to acquire Inari Medical, Inc. for approximately $4.9 billion and to sell its U.S. Spinal Implants business to Viscogliosi Brothers, LLC.
- Legal and Regulatory: The company is investigating potential violations of the Foreign Corrupt Practices Act (FCPA) in certain foreign countries. It also faces ongoing product liability litigation regarding Rejuvenate and ABG II hip stems, with an accrual of $202 million as of year-end.
- Capital Allocation: Stryker prioritizes acquisitions, dividends, and share repurchases. No shares were repurchased in 2024, but $1,219 million was paid in dividends. The company maintains a $2,250 million revolving credit facility.
- Risks: Key risks include supply chain disruptions, inflationary pressures on manufacturing costs, foreign currency fluctuations, and the impact of healthcare cost containment measures globally.
Investor Verification Checklist
- Spinal Implants Sale: Verify the closing timeline and final consideration for the sale of the U.S. Spinal Implants business to Viscogliosi Brothers, LLC.
- Inari Acquisition: Monitor the progress of the $4.9 billion Inari Medical tender offer and regulatory approvals required for closing in Q1 2025.
- FCPA Investigation: Track updates on the ongoing FCPA investigation and potential financial impact on future periods.
- Product Liability Reserves: Review future filings for changes in the $202 million accrual related to hip stem product liability claims.
- Adjusted vs. GAAP: Note the significant divergence between GAAP EPS ($7.76) and Adjusted EPS ($12.19) due to non-recurring impairment charges.